Innate Lead Candidate Fails In Head And Neck Cancer But Partner AZ Offers Hope In NSCLC

 
• By Ayisha Sharma

Innate’s lead candidate has reached the end of the road in head and neck carcinoma after a disappointing interim Phase III trial analysis but hope remains that a combination with partner AstraZeneca's Imfinzi could succeed elsewhere.  

Paper lungs with a hole on one side, depicting lung cancer, on blue background
AstraZeneca Hopes To Position Imfinizi In The Adjuvant Lung Cancer Setting • Source: Shutterstock

More from Clinical Trials

More from R&D